



EDITION

15th MILAN CONGRESS ON
**Innovative
Anticancer
Therapy**

SCIENTIFIC PROGRAM



RESIDENTIAL CONGRESS 2025

January 23th from 05.00 p.m. to 06.00 p.m.

January 24th from 09.30 a.m. to 05.45 p.m.

Aula Magna Gianni Bonadonna
Fondazione IRCCS Istituto Nazionale dei Tumori
Via G. Venezian, 1 - MILAN

Sistema Socio Sanitario

 **Fondazione IRCCS**
Istituto Nazionale dei Tumori

 **Regione**
Lombardia



PATRONAGE REQUESTED



Sistema Socio Sanitario



Fondazione IRCCS
Istituto Nazionale dei Tumori



Regione
Lombardia





RATIONALE

The 15th "Milan Congress on Anticancer Innovative Therapy" Conference will involve leading international experts in the field of immuno-oncology and cancer cell signaling to understand the potential, opportunities and challenges of the immunotherapy and targeted therapies.

The increasing knowledge of the molecular mechanisms responsible for neoplastic transformation, the biology of cancer cells, and the immunological mechanisms regulating tumor-host interaction, allowed us to identify and apply more effective anti-cancer biological and immunological treatments. To date, the immuno-biotherapy is a continuously evolving treatment modality and it is currently integrated into the treatment algorithms of several different tumor types.

This meeting will provide you with the latest insights in CAR T and reported clinical data, making it an invaluable opportunity to stay at the forefront of this rapidly evolving field. In addition, novel treatments based on anticancer RNA-vaccination or on radioligands have been recently introduced in the clinical practice. Rationale, *pro and contra* and the identification of particular subset of patients who could actually benefit from these approaches will be discussed. Finally, in the meeting will be discussed how the progress in the molecular characterization of the tumor based on institutional tumor molecular boards might allow the identification of novel therapeutic targets.

This conference explores topics that will appeal to clinicians, as well as, basic, translational, and clinical scientists ranging from academics to industry. As in the past, the meeting will provide a highly interactive forum in which leading experts will discuss clinical and pre-clinical data, providing the audience with a broad overview of the most recent achievements in cancer biologic and immunologic therapy.

We genuinely believe that this event presents an amazing opportunity for you to expand your knowledge, network with industry leaders, and contribute to the advancement in the biology and the treatment of cancer patients.



SCIENTIFIC HEADS

FILIPPO DE BRAUD (Milan, Italy)

MICHELE DEL VECCHIO (Milan, Italy)

MASSIMO DI NICOLA (Milan, Italy)

SCIENTIFIC BOARD

GIOVANNI APOLONE (Milan, Italy)

FILIPPO DE BRAUD (Milan, Italy)

MICHELE DEL VECCHIO (Milan, Italy)

MASSIMO DI NICOLA (Milan, Italy)

GIANPIETRO DOTTI (Chapel Hill, USA)

LUCA GATTINONI (Regensburg, Germany)



FACULTY

- **Giovanni APOLONE**
Milan, Italy
- **Christian BUCHHOLZ**
Langen, Germany
- **George COUKOS**
Losanna, Switzerland
- **Romano DANESI**
Milan, Italy
- **Filippo DE BRAUD**
Milan, Italy
- **Michele DEL VECCHIO**
Milan, Italy
- **Massimo DI NICOLA**
Milan, Italy
- **Giampiero DOTTI**
Chapel Hill, USA
- **Paolo FIORINA**
Milan, Italy
- **Luca GATTINONI**
Regensburg, Germany
- **Marco MACCAURO**
Milan, Italy
- **Massimo MASSAIA**
Cuneo, Italy
- **Paul NATHAN**
Mount Vernon, UK
- **Hendrik POECK**
Regensburg, Germany
- **Daniel POWELL**
Philadelphia, USA



23th JANUARY 2025 · SCIENTIFIC PROGRAM

16.30-17.00 Registration

17.00-17.15 Introduction to the Lecture
Michele DEL VECCHIO (Milan, Italy)

17.15-18.00 New frontiers in adoptive cell therapy in cancer
George COUKOS (Losanna, Switzerland)

18.00 Welcome Cocktail



24th JANUARY 2025 · SCIENTIFIC PROGRAM

09.15-09.30 Welcome Address
Giovanni APOLONE (Scientific Director,
Fondazione IRCCS Istituto Tumori, Milan, Italy)

I SESSION: New insights on CART and immunotherapy

Chairmen: **Filippo DE BRAUD** (Milan, Italy), **Giampiero DOTTI** (Chapel Hill, USA)

09.30-10.00 Are the CAR-NKs more effective of CARTs?
Giampiero DOTTI (Chapel Hill, USA)

10.00-10.15 Discussion

10.15-10.45 The role of novel axis GLP-1R/L in diabetes and cancer
Paolo FIORINA (Milan, Italy)

10.45-11.00 Discussion

11.00-11.30 Recruiting and strengthening endogenous T cells
to enhance CAR T cell activity in solid tumors
Daniel POWELL (Philadelphia, USA)

11.30-11.45 Discussion

11.45-12.15 In-vivo of CART cells engineering
Christian BUCHHOLZ (Langen, Germany)

12.15-12.30 Discussion

12.30-14.30 Lunch

II SESSION: Clinical translation

Chairmen: **Massimo MASSAIA** (Turin, Italy), **Luca GATTINONI** (Regensburg, Germany)

14.30-15.00 Radioligands: a new frontier in anticancer treatment
Marco MACCAURO (Milan, Italy)

15.00-15.15 Discussion

15.15-15.45 Modulation of T cell-dependent cancer therapies
by microbial metabolites and STING
Hendrik POECK (Regensburg, Germany)

15.45-16.00 Discussion

16.00-16.30 Uveal melanoma: Therapeutic progress and perspectives
Paul NATHAN (Mount Vernon, UK)

16.30-16.45 Discussion

16.45-17.00 The role of tumor molecular board to identify novel target
for phase I trials
Romano DANESI (Milan, Italy)

17.15-17.30 Discussion

17.30-17.50 Neoadjuvant and adjuvant therapy in melanoma: updates
Michele DEL VECCHIO (Milan, Italy)

17.50-18.00 Discussion

18.00-18.10 Conclusions
Massimo DI NICOLA (Milan, Italy)
Delivery and compilation CME questionnaire

GENERAL INFORMATIONS

Date

Thursday, 23th January 2025

from 05.00 p.m. to 06.00 p.m.

Friday, 24th January 2025

from 09.30 a.m. to 05.45 p.m.

Congress Venue

Aula Magna Gianni Bonadonna

Fondazione IRCCS Istituto Nazionale dei Tumori

Via G. Venezian, 1 - MILAN

Official language

English

CME Provider Nr. 265

Organizing Secretariat



Nadirex International Srl

Via Riviera 39 · 27100 Pavia

Project Manager: Dr.ssa Gloria Molla

Mob 347 8589333 - gloria.molla@nadirex.com

www.nadirex.org

Registration

The registration is free and includes:

- Participation in the conference work
- Congress Kit
- Certificate of Attendance
- CME credits Certificate
- Welcome coffee and lunch as scheduled
- Post-event educational material
- Hostess assistance

Registration instructions

Registration is free and can be made on-line at www.nadirex.org

The Congress is not by direct invitation of the Sponsor.



CME INFORMATIONS

Id ECM: 265-436167

CME credits: 9

- **Participants:** 100
- **Learning hours:** 8
- **Educational goal:** Nr. 3 - Clinical documentation. Diagnostic and rehabilitative clinical-assistance paths, assistance profiles - treatment profiles

• **Addresses of the Congress**

The Congress is addressed to the following figures:

- Medico Chirurgo
(Discipline: tutte le discipline)
- Psicologo (Psicoterapia, Psicologia)
- Biologo - Biotecnologo (Biologo - Biotecnologo)
- Tecnico Sanitario Laboratorio Biomedico (Tecnico Sanitario Laboratorio Biomedico)
- Tecnico Sanitario di Radiologia Medica (Tecnico Sanitario di Radiologia Medica)
- Farmacista (Farmacista Pubblica del SSN, Farmacista Territoriale)
- Chimico (Chimica Analitica)

In order to obtain CME credits, participants must:

- Participate in 90% of training activities
- Complete the ECM questionnaire correctly (the attribution of credits is subject to exceeding 75% correct answers)
- Fill in the RES event perceived quality sheet
- Fill in the training needs survey form
- Sign the attendance register at the beginning and end of the work
- Having completed the recruitment declaration by Sponsor (to be delivered at the beginning of the day)

WITH THE UNRESTRICTED
EDUCATIONAL GRANTS OF:

Platinum



Gold



Silver

IMMUNOCORE

Others



Pierre Fabre
Innovative Oncology